Hepatic PDIA5 improves hyperglycaemia and insulin resistance through stabilisation of ATF6
- 1Department of Endocrinology and Metabolism, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China
- 2Institute of Metabolism and Regenerative Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract
Aims/hypothesis: Dysregulation of hepatic glucose production, primarily driven by aberrantly elevated gluconeogenesis, is a core pathological feature of type 2 diabetes. However, the molecular mechanisms governing this process remain incompletely understood. Protein disulfide isomerase A5 (PDIA5) is ubiquitously expressed, but its specific function in hepatic metabolism is unknown. We hypothesised that PDIA5 plays a critical role in regulating hepatic gluconeogenesis, and that its dysregulation contributes to hyperglycaemia.
Methods: We assessed hepatic PDIA5 expression in liver biopsies from individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and from mouse models of type 2 diabetes. The function of PDIA5 was investigated using adenoviral-mediated overexpression in the livers of male mice fed a high-fat diet (HFD) and in mouse primary hepatocytes (MPHs). Metabolic phenotypes were characterised through glucose, insulin and pyruvate tolerance tests and hyperinsulinaemic–euglycaemic clamps. Mechanistic investigations in MPHs and HEK293T cells, involving co-immunoprecipitation, ubiquitination assays and chromatin immunoprecipitation, were used to delineate the PDIA5–ATF6 (activating transcription factor 6) signalling axis. The physiological necessity for PDIA5 was confirmed using whole-body Pdia5 knockout male mice and adenovirus-mediated liver-specific Pdia5-deficient female mice.
Results: Hepatic PDIA5 expression was significantly reduced in both individuals with MASLD and diabetic mice. Hepatic overexpression of PDIA5 in HFD-fed mice ameliorated hyperglycaemia and improved glucose homeostasis by suppressing expression of gluconeogenic genes (Pck1 and G6pc1) and glucose production. Mechanistically, PDIA5 was found to physically interact with and stabilise the endoplasmic reticulum stress sensor ATF6, which is a known suppressor of gluconeogenesis. PDIA5 shields ATF6 from the E3 ubiquitin ligase synoviolin 1 (SYVN1), thereby inhibiting its ubiquitination and subsequent proteasomal degradation. This stabilisation of ATF6 attenuated recruitment of the co-activator CRTC2 to gluconeogenic promoters and suppressed the PERK–TRB3 signalling axis, enhancing hepatic insulin sensitivity. Importantly, knockdown of ATF6 abolished the protective effects of PDIA5 on glucose metabolism. Conversely, genetic deletion of Pdia5 exacerbated glucose intolerance in HFD-fed mice.
Conclusions/interpretation: Our findings identify a novel PDIA5–SYVN1–ATF6 regulatory axis that is crucial for maintaining hepatic glucose homeostasis. These results establish PDIA5 as a critical molecular checkpoint linking hepatic lipid overload to glucose dysregulation, and highlight it as a potential therapeutic target for type 2 diabetes.
Graphical Abstract:
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00125-026-06862-8.
Related
- Dietary protein source dictates the impact of obesogenic diets on hepatic steatosis and insulin resistance via carnitine-dependent regulation of acetyl-CoA carboxylase
- Sequence-aware genotyping improves the accuracy of molecular markers associated with cassava mosaic disease resistance loci
- Delayed Diagnosis of 48, XXYY Syndrome in an Adult Male Presenting with Severe Insulin Resistance and Hypergonadotropic Hypogonadism: A Case Report
- The role of insulin resistance in the development of hepatocellular carcinoma with computational analysis of IRS-1 interaction with HCV genotype 3 core protein
- Effects of a Nutrigenetic Diet on Fat Mass Loss, Insulin Resistance, and Subclinical Inflammation in Adults with Abdominal Obesity: A Randomized Controlled Trial—The INNUPREC Study
BibTeX
@article{wan2026hepatic,
title = {{Hepatic PDIA5 improves hyperglycaemia and insulin resistance through stabilisation of ATF6}},
author = {Jintao Wan and Mingliang Zhang and Teng Ma and Qianqian Yang and Jinghao Cai and Jiaying Ni and Yiming Si and Cheng Li and Yaxin Wang and Yan Lu and Jun Yin and Jian Zhou},
journal = {Diabetologia},
year = {2026},
month = sep,
doi = {10.1007/s00125-026-06862-8},
url = {https://doi.org/10.1007/s00125-026-06862-8},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Hepatic PDIA5 improves hyperglycaemia and insulin resistance through stabilisation of ATF6
AU - Jintao Wan
AU - Mingliang Zhang
AU - Teng Ma
AU - Qianqian Yang
AU - Jinghao Cai
AU - Jiaying Ni
AU - Yiming Si
AU - Cheng Li
AU - Yaxin Wang
AU - Yan Lu
AU - Jun Yin
AU - Jian Zhou
PY - 2026
DA - 2026/09/17
JO - Diabetologia
DO - 10.1007/s00125-026-06862-8
UR - https://doi.org/10.1007/s00125-026-06862-8
AB - Aims/hypothesis: Dysregulation of hepatic glucose production, primarily driven by aberrantly elevated gluconeogenesis, is a core pathological feature of type 2 diabetes. However, the molecular mechanisms governing this process remain incompletely understood. Protein disulfide isomerase A5 (PDIA5) is ubiquitously expressed, but its specific function in hepatic metabolism is unknown. We hypothesised that PDIA5 plays a critical role in regulating hepatic gluconeogenesis, and that its dysregulation contributes to hyperglycaemia. Methods: We assessed hepatic PDIA5 expression in liver biopsies from individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and from mouse models of type 2 diabetes. The function of PDIA5 was investigated using adenoviral-mediated overexpression in the livers of male mice fed a high-fat diet (HFD) and in mouse primary hepatocytes (MPHs). Metabolic phenotypes were characterised through glucose, insulin and pyruvate tolerance tests and hyperinsulinaemic–euglycaemic clamps. Mechanistic investigations in MPHs and HEK293T cells, involving co-immunoprecipitation, ubiquitination assays and chromatin immunoprecipitation, were used to delineate the PDIA5–ATF6 (activating transcription factor 6) signalling axis. The physiological necessity for PDIA5 was confirmed using whole-body Pdia5 knockout male mice and adenovirus-mediated liver-specific Pdia5-deficient female mice. Results: Hepatic PDIA5 expression was significantly reduced in both individuals with MASLD and diabetic mice. Hepatic overexpression of PDIA5 in HFD-fed mice ameliorated hyperglycaemia and improved glucose homeostasis by suppressing expression of gluconeogenic genes (Pck1 and G6pc1) and glucose production. Mechanistically, PDIA5 was found to physically interact with and stabilise the endoplasmic reticulum stress sensor ATF6, which is a known suppressor of gluconeogenesis. PDIA5 shields ATF6 from the E3 ubiquitin ligase synoviolin 1 (SYVN1), thereby inhibiting its ubiquitination and subsequent proteasomal degradation. This stabilisation of ATF6 attenuated recruitment of the co-activator CRTC2 to gluconeogenic promoters and suppressed the PERK–TRB3 signalling axis, enhancing hepatic insulin sensitivity. Importantly, knockdown of ATF6 abolished the protective effects of PDIA5 on glucose metabolism. Conversely, genetic deletion of Pdia5 exacerbated glucose intolerance in HFD-fed mice. Conclusions/interpretation: Our findings identify a novel PDIA5–SYVN1–ATF6 regulatory axis that is crucial for maintaining hepatic glucose homeostasis. These results establish PDIA5 as a critical molecular checkpoint linking hepatic lipid overload to glucose dysregulation, and highlight it as a potential therapeutic target for type 2 diabetes. Graphical Abstract: Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00125-026-06862-8.
SN - 0012-186X
SN - 1432-0428
ER -